Back to Agenda
The Needs of the Payers Shape the Evidence for Market Access
Session Chair(s)
Stanislav Primozic
Head, Sector for Pharmacoeconomics, Pharmacovigilance and HTA
Agency for Medicinal Products and Medical Devices, Slovenia
Session in development
Learning Objective : Understand the EU Adaptive Pathway and its potential impact on member state’s decisions on pricing and reimbursement
Speaker(s)
How Companies Fit All Evidence Requirements into One Development Plan
Marlene Gyldmark
F. Hoffmann- La Roche AG, Switzerland
How Will Payers React to the Future of Drug Development?
Steffen Thirstrup, MD, PhD
European Medicines Agency, Netherlands
Chief Medical Officer
How Can a Joint Regulatory-HTA Scientific Advice Process (Both Pre- and Post-Launch) Help Deliver the Right Evidence?
Jane Moseley, DrMed, MSc
European Medicines Agency, Netherlands
Head of Inspections
Have an account?